Tags Posts tagged with "Growth"


1 3645

The marijuana industry is getting ready to take a step forward in its venture for validity and long-term stability. The American Society for Testing and Materials (ASTM International) recently announced that it will put a committee of industry representatives and experts together to create a set of guidelines in six technical areas: Indoor and outdoor horticulture and agriculture, Quality management systems, Laboratory standards, Processing and handling, Security and transportation, Personal training/ assessment and credentialing.

ASTM International’s announcement is welcome news to an industry that operates with no federal oversight. Uniform standards should provide additional assurance to insurance carriers, the medical community, and the federal government as the pathway to full legalization continues. There are definite benefits to the marijuana industry from the creation of published standards, which should assist manufacturers and distributors in establishing baselines for testing and quality control, provide practitioners and dispensaries a standard by which to prescribe and dispense, and allow insurers to better underwrite the risks being covered.

The advancement and stability of the marijuana market stands to improve when insurers are more confident in the ability to use objective risk management metrics through accepted practices and standards for analysis, manufacturing, and transportation of these products. This should encourage more carriers to write policies for the cannabis industry.
Pesticides – Distributors, prescribers, users, and insurers want to be assured their product is free of toxic sprays and treatments.

Contaminates – Distributors, prescribers, users, and insurers need assurance that the products are free of contamination, such as mold, bacteria, yeast, and other microorganisms. There is growing demand from medical cannabis patients for higher-quality packaging that either displays an expiration date or provides greater protection from oxidation and degradation over time.

Potency – Not all marijuana plants, products, and derivatives are the same. They differ in their pharmacology, potency and appearance. They also can be distinguished by variables such as whether they are farmed outdoors or indoors, or grown organically. Distributors, prescribers, users, and insurers need to know that the potency is accurate.
Worker Safety – A 2017 study by New Frontier Data anticipates that marijuana industry hiring will eclipse manufacturing hiring by the year 2020. Inherent in this growth is an increased potential for workplace injuries and the risks related to marijuana businesses and their carriers. The U.S. market needs to know that employees are receiving the necessary training, instruction, education and protection in the cultivation, transporting, packaging, extracting and sales operations. ASTM International is expected to produce standards, ranging from best manufacturing practices to protective equipment and proper ventilation, that address workplace dangers.

Labeling – Every marijuana-legal state currently has, or is drafting, its own labeling requirements. A uniform labeling standard will give distributors, prescribers, and insurers confidence that the product is labeled consistently with a national standard. Quality-Control Testing – Ensuring a relatively uniform method of testing from state to state, and facility to facility, should improve product quality and consistency, and reduce the exposure from product liability and contamination claims along with the potential for product recalls. Reliably consistent testing also will allow patient-users to evaluate levels of all known useful cannabinoids, including levels of THC, CBD, and CBN, to help them choose strains or products better suited to their needs.

Twenty-eight states have regulated or decriminalized marijuana and/or its derivatives. The marijuana market cannot reach its full potential, however, without widespread acceptance from the medical community and the insurance industry. As Corey Tobin of Bolton & Company, a full-service insurance brokerage, explains, “Insurers usually move slowly, although ASTM International’s creation of a set of standards will help the insurers get a better understanding of the needs of these corporations.” While drawing up and examining the guidelines will take time, the design of uniform standards will be an important step forward for the industry in terms of its its long-term stability and validity.

0 5674

1. T.V. Show With Cannabis Theme

Over ten years ago Showtime released Weeds, a series centered on a suburban mother that sold marijuana as her full-time career. Even with its risque topic, it was considered revolutionary at the time. HBO has High Maintenance out currently. Adam Scott from Parks and Recreation was given the greenlight from NBC to create a show called Buds about a dispensary in Denver, however there is no release date for the comedy.

2. L.A. Will Become Cannabis Capital

Chief Executive Officer of marijuana investment firm MedMen Capital, Adan Bierman, believes that Los Angeles will steal the spotlight from Denver, Colorado. Bierman said that by some estimates, Los Angeles’s medical cannabis market alone is already close to a billion dollars, easily outweighing Colorado’s market.

3. Growth Of Specialty Cannabis

Chief Marketing Officer of vaporizer distributor Greenlane, Sasha Kadey, said he predicts that as market supplies grow, prices will fall, becoming commodities in the eyes of the consumers. “This is leading to premiumization,” he stated. “Much like the alcohol industry experienced during its maturation, with producers now seeking to differentiate with premium packaging, brand building, so called “seed to sale” storytelling, and other value adds.” Some farmers will stress their organic features while others push celebrity endorsements. 2017 will be the year of the specialty classifications of marijuana.

4. Interest Increases For CBD oil

It is predicted that interest in cannabinoids (CBD) will increase, even with the DEA and the Hemp Industries Association fighting over the legality of marijuana extracts. Chief executive officer of biotech company Kalytera , Seth Yakatan said, “With AG Sessions and the DEA’s clarification that plant derived CBD isn’t legal federally, there will likely be interest in synthetic forms of CBD, which is what Kalytera has been testing the efficacy of for a few years.”

Subscribe Now & Begin Receiving Marijuana Stocks News, Articles, Trade Alerts & MORE, all 100% FREE!

We are your #1 source for all things Marijuana Stocks, Subscribe Below!

Privacy Policy: We will NEVER share, sell, barter, etc. any of our subscribers information for any reason ever! By subscribing you agree we can send you via email our free e-newsletter on marijuana stocks related, articles, news and trade alerts. Further questions please contact privacy@marijuanastocks.com
Ad Placements